Thomas J. Tucker

Dr. Thomas J. Tucker


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Circulation
Verified
Journal Article
Open access
DJDouglas G. Johns
Douglas G. Johns
LCLouis-Charles Campeau
Louis-Charles Campeau
PBPuja Banka
Puja Banka
ABAn Bautmans
An Bautmans
TBTjerk Bueters
Tjerk Bueters
HWHarold B. Wood
Harold B. Wood
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.

27 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TTThomas J. Tucker
Thomas J. Tucker
MEMark W. Embrey
Mark W. Embrey
CACandice Alleyne
Candice Alleyne
RARupesh P. Amin
Rupesh P. Amin
ABAlan Bass
Alan Bass
AWAbbas Walji
Abbas Walji

10 November 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CACandice Alleyne
Candice Alleyne
RARupesh P. Amin
Rupesh P. Amin
BBBhavana Bhatt
Bhavana Bhatt
EBElisabetta Bianchi
Elisabetta Bianchi
JBJ. Craig Blain
J. Craig Blain
TTThomas J. Tucker
Thomas J. Tucker

1 October 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TTThomas J. Tucker
Thomas J. Tucker
JSJohn T. Sisko
John T. Sisko
RTRobert M. Tynebor
Robert M. Tynebor
TWTheresa M. Williams
Theresa M. Williams
PFPeter J. Felock
Peter J. Felock
YYYouwei Yan
Youwei Yan

1 May 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TTThomas J. Tucker
Thomas J. Tucker
SSSandeep Saggar
Sandeep Saggar
JSJohn T. Sisko
John T. Sisko
RTRobert M. Tynebor
Robert M. Tynebor
TWTheresa M. Williams
Theresa M. Williams
YYYouwei Yan
Youwei Yan

31 May 2019 in Molecules
Verified
Journal Article
Open access
PDF file
BABethany Algayer
Bethany Algayer
AOAnn O’brien
Ann O’brien
AMAaron Momose
Aaron Momose
DMDennis J. Murphy
Dennis J. Murphy
WPWilliam Procopio
William Procopio
TTThomas J. Tucker
Thomas J. Tucker
Delivery of macromolecular cargos such as siRNA to the cytosol after endocytosis remains a critical challenge. Numerous approaches including viruses, lipid nanoparticles, polymeric constructs, and various peptide-based approaches have yet to yield a general solution to this delivery issue. In this manuscript, we describe our efforts to design novel endosomolytic peptides that could be used to facilitate the release of cargos from a late endosomal compartment. These amphiphilic peptides, based on a chimeric influenza hemagglutinin peptide/cell-penetrating peptide (CPP) template, utilize a pH-triggering mechanism in which the peptides are protonated after acidification of the endosome, and thereby adopt an alpha-helical conformation. The helical forms of the peptides are lytically active, while the non-protonated forms are much less or non-lytically active at physiological pH. Starting from an initial lead peptide (INF7-Tat), we systematically modified the sequence of the chimeric peptides to obtain peptides with greatly enhanced lytic activity that maintain good pH selectivity in a red blood cell hemolysis assay.